cas 948349-66-4|| where to buy ethyl 4-bromo-3-(ethoxymethyl)benzoate

Название продукции:ethyl 4-bromo-3-(ethoxymethyl)benzoate

IUPAC Name:ethyl 4-bromo-3-(ethoxymethyl)benzoate

: CAS：948349-66-4; Молекулярная формула：C12H15BrO3; Чистота：95%+

Упаковочная единица	Доступно для заказа	Цена ($)	Количество
CM1015264-5g	in stock	ǶƦȺ

Только для использования в НИОКР..

Форма запроса

Химическое название

Номер CAS

Количество*

Необходимые спецификации*
(% пробы, категория материала и т.д.)

Контактное лицо*

Электронная почта*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 948349-66-4 regularly via the above email.

Дополнительные примечания

Verification code*

refresh

: Номер CAS:948349-66-4; Молекулярная формула:C12H15BrO3; Точка плавления:-; Smiles-код:CCOCC1=C(C=CC(=C1)C(=O)OCC)Br; Плотность:

: Номер в каталоге:CM1015264; Молекулярная масса:287.15; Точка кипения:; Номер Mdl:; Хранение:

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Sparsentan; CSL Vifor and Travere Therapeutics announce European Commission approves FILSPARI(sparsentan) for the treatment of IgA Nephropathy (IgAN). First non-immunosuppressive therapy for the treatment of IgAN approved in Europe.
Sparsentan is a novel, non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist with high selectivity for the endothelin A receptor (ETAR) and the angiotensin II subtype 1 receptor (AT1R). Pre-clinical data have shown that blockade of both endothelin type A and angiotensin II type 1 pathways in forms of rare chronic kidney disease, protects podocytes, prevents glomerulosclerosis and mesangial cell proliferation, and reduces proteinuria.